ID   UCD4
AC   CVCL_ZV41
DR   cancercelllines; CVCL_ZV41
DR   Wikidata; Q98133838
RX   PubMed=32576280;
CC   Characteristics: Established from a patient-derived xenograft.
CC   Characteristics: ER/PR-positive and ERBB2-negative.
CC   Doubling time: 95.9 hours, 89.3 hours (Note=With 17-beta-estradiol) (PubMed=32576280).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Lys585Asnfs*3 (c.1755_1759delGAAAA); ClinVar=VCV000037754; Zygosity=Unspecified (PubMed=32576280).
CC   Sequence variation: Mutation; HGNC; HGNC:3467; ESR1; Simple; p.Asp538Gly (c.1613A>G); Zygosity=Unspecified (PubMed=32576280).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   68Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 19-12-24; Version: 8
//
RX   PubMed=32576280; DOI=10.1186/s13058-020-01300-y; PMCID=PMC7310532;
RA   Finlay-Schultz J., Jacobsen B.M., Riley D., Paul K.V., Turner S.,
RA   Ferreira-Gonzalez A., Harrell J.C., Kabos P., Sartorius C.A.;
RT   "New generation breast cancer cell lines developed from
RT   patient-derived xenografts.";
RL   Breast Cancer Res. 22:68.1-68.12(2020).
//